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Abstract
Background: Controlling blood pressure with drugs is a key aspect of cardiovascular disease
prevention, but until recently has been the sole preserve of health professionals. Self-management
of hypertension is an under researched area in which potential benefits for both patients and
professionals are great.
Methods and design: The telemonitoring and self-management in hypertension trial
(TASMINH2) will be a primary care based randomised controlled trial with embedded economic
and qualitative analyses in order to evaluate the costs and effects of increasing patient involvement
in blood pressure management, specifically with respect to home monitoring and self titration of
antihypertensive medication compared to usual care. Provision of remote monitoring results to
participating practices will ensure that practice staff are able to engage with self management and
provide assistance where required. 478 patients will be recruited from general practices in the
West Midlands, which is sufficient to detect clinically significant differences in systolic blood
pressure between self-management and usual care of 5 mmHg with 90% power. Patients will be
excluded if they demonstrate an inability to self monitor, their blood pressure is below 140/90 or
above 200/100, they are on three or more antihypertensive medications, have a terminal disease
or their blood pressure is not managed by their general practitioner.
The primary end point is change in mean systolic blood pressure (mmHg) between baseline and
each follow up point (6 months and 12 months). Secondary outcomes will include change in mean
diastolic blood pressure, costs, adverse events, health behaviours, illness perceptions, beliefs about
medication, medication compliance and anxiety. Modelling will evaluate the impact of costs and
effects on a system wide basis. The qualitative analysis will draw upon the views of users, informal
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BMC Cardiovascular Disorders 2009, 9:6 http://www.biomedcentral.com/1471-2261/9/6carers and professionals regarding the acceptability of self-management and prerequisites for future
widespread implementation should the trial show this approach to be efficacious.
Discussion: The TASMINH2 trial will provide important new evidence regarding the costs and
effects of self monitoring with telemonitoring in a representative primary care hypertensive
population.
Trial Registration: ISRCTN17585681
Background
National and international surveys have found that
despite some recent improvements, the blood pressure of
many people with hypertension remains poorly control-
led. [1,2] This is despite evidence that reduction to <140/
90 mmHg is achievable and results in important benefits
in terms of morbidity and mortality.[3] Adequate blood
pressure control is a prerequisite if cardiovascular disease
is to be reduced in line with recent UK policy targets.[4,5]
There are many potential reasons for sub-optimal blood
pressure control. Hypertension is largely asymptomatic
with little biological feedback to patients in terms of
blood pressure control. Treatment is generally life long
and may be associated with dose related side effects. It is
therefore perhaps not surprising that adherence to antihy-
pertensive medication is often poor with around half of
hypertensive patients discontinuing new prescriptions for
antihypertensive drugs in the first six months.[6]
It is not simply a question of motivating patients.
Research in UK general practice has shown a lack of pro-
fessional action in the presence of high recorded blood
pressures along with a reluctance to prescribe for isolated
systolic hypertension.[7] Fear of side effects may be one
reason for this inaction although modern treatment trials
have shown relatively modest levels of side effects.[2]
Workload in primary care has been cited as another rea-
son for poor performance, with the average practice hav-
ing to provide care for several hundred people with
hypertension.[8] Novel approaches for the management
of high blood pressure are therefore required.
There is good evidence for both pharmacological and
non-pharmacological interventions.[9] The advent of
accurate and easy to use automated sphygmomanometers
means that blood pressure measurement need no longer
be confined to professionals. Health behaviour models
suggest that increased patient involvement in disease
management will result in cues to action and increased
self-efficacy with improved adherence to treatment and
beneficial changes in other health behaviours such as in
diet and exercise.[10]
Four previous randomised studies have evaluated the effi-
cacy of telemonitoring in conjunction with self-monitor-
ing of hypertension and other interventions but none
have been adequately powered, followed up for more
than six months, or set in the UK. [11-14](Table 1) Fried-
man's 1996 study randomised 267 hypertensive patients
under the care of community physicians to self-monitor-
ing with an interactive telephone reporting system or
usual care. Intervention patients measured their own
blood pressure on a weekly basis and reported the results
via the "TLC" computerised telephone system. [11] This
system, as well as recording blood pressure, provided
automated feedback to the subject before transmitting
results to an individual's physician. The authors found a
significant benefit from the intervention in terms of
diastolic blood pressure once adjusted for baseline differ-
ences between the groups. No such difference was seen for
systolic blood pressure. Roger and colleagues studied 121
hypertensive people recruited from a hospital clinic. [12]
Automated blood pressure readings were transmitted to
the study centre via telephone. The intervention group
had slightly reduced (3 mmHg) mean arterial pressure as
measured by twenty-four hour blood pressure monitoring
which remained significant after adjustments for baseline
differences between groups. The final two trials by Mehos
(34 patients) [13] and Artinian (26 patients) [14] were
too small to draw conclusions from other than the fact
that community based telemonitoring of blood pressure
is feasible in a range of settings.
A further study [15] by Zarnke and colleagues in Canada
has evaluated self-management of hypertension (Table 1).
31 patients with hypertension were randomised between
usual care and self-directed adjustment of medication
using a fixed set of antihypertensive medication. Follow-
up after eight weeks showed a small drop in mean arterial
pressure in the intervention group compared to control.
These studies have been combined with other self-moni-
toring work in two systematic reviews. [16,17] These
showed that, in common with other non-pharmacologi-
cal interventions, self-monitoring, with or without telem-
onitoring, has a modest effect on blood pressure. OnePage 2 of 9
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ing in a UK primary care setting. [18] This work by our
group showed that people with hypertension were able
and willing to self-monitor blood pressure, and that the
small reductions in blood pressure were probably medi-
ated through lifestyle changes and that self-monitoring is
cost effective.
The studies discussed above have all been quantitative
studies and there has been very limited exploration of
patients' views of self-monitoring. [19,20] There is cur-
rently no information on potential issues arising from
self-management of hypertension from the perspective of
patients, carers or health care providers.
Therefore, the TASMINH2 study is an extension of our
previous work, expanding the intervention from self mon-
itoring to self management to include not only self mon-
itoring of blood pressure, but telemonitoring and self
titration of antihypertensive medication, with the expecta-
tion that this will result in larger reductions of blood pres-
sure.
Methods
Study Aims, Research Questions, and Outcomes
The primary aim of TASMINH2 is to compare self man-
agement with usual care in the control of hypertension.
The trial has four main research questions:
1) Does self-management with telemonitoring and titra-
tion of antihypertensive medication by people with
poorly controlled hypertension result in better control of
blood pressure?
2) Is self-management with telemonitoring and titration
of antihypertensive medication by people with poorly
controlled hypertension cost effective?
3) Is self-management with telemonitoring and titration
of antihypertensive medication achievable in routine
practice and is it acceptable to patients?
Table 1: Summary of randomised studies evaluating self-monitoring with telemonitoring or self-management
Study Number of 
subjects
Mean age
Length of follow 
up
Type & 
frequency of 
BP self 
measurement
Frequency of 
other input 
(either as co-
intervention or 
outcome 
measurement)
Was physician 
adjusting 
medication 
aware of self 
measurement 
readings
Outcome 
measurement
Outcome of study
Friedman 1996
US [11]
267 patients under 
care of community 
physicians
Age 77
6 months
Automated
Weekly
(?upper arm)
Self report of BP, 
adherence etc via 
computerised 
telephone system 
(TLC) on a weekly 
basis with automated 
feedback
"TLC" data 
transmitted to 
patient's own 
physician
BP measured on 
home visit; protocol 
for measurement 
not clear if blinded
Small drop in DBP 
only after 
adjustment (mean 
adjusted DBP 
change 5.2 mmHg vs 
0.8 mmHg, No CIs, 
p = 0.02)
Mehos [13]
2000
US
36 primary care 
patients with 
poorly controlled 
hypertension
59 years
6 months
Manual 
electronic
Daily
Upper arm
Monthly telephone 
calls to coordinate 
treatment changes
All received 
counselling on ht rx 
and lifestyle
Yes not clear if blinded No CI s or p quoted
Rogers [12]
2001
US
121 hypertensive 
patients from 
hospital clinic
61 years
At least 8 weeks
Automated
3 days per week
(? upper arm)
Transmission of 
results of BP down 
phone line
Monthly reports to 
patient and physician 
electronically 
generated
Yes Main outcome 
ambulatory BP 
monitoring pre and 
post intervention 
which physicians 
were blinded to
Reduction in MAP of 
3 mmHg, 
(no CI, p = 0.013)
Artinian [14]
2001
US
26 African 
American with 
hypertension 
attending a family 
community centre
Automated
At least 3 days 
per week
Upper arm
Transmission of BP 
results down phone 
line each Friday with 
automated feedback 
to patients
Additional feedback 
via study nurse
Yes Clinic measurement 
before and after 
measured by 
blinded investigator
Pilot study: no 
formal comparison 
of between group 
BP drop.
Zarnke [15]
1997
Canada
31 hypertensive 
primary care 
patients
55 years
8 weeks
Electronic
Twice daily
(?upper arm)
Self directed 
adjustment of 
medication
Self help advice to all
Yes if consulted 
when patient had 
already tried to 
change treatment
Mercury sphyg; not 
clear if blinded but 
externally 
measured. Also 
ambulatory BP
Intervention group 
had lower mean 
ambulatory MAP.(-
0.95 vs +1.9 mmHg, 
No CI, p = 0.039)Page 3 of 9
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mal carers and healthcare professionals of self-manage-
ment with telemonitoring and titration of
antihypertensive medication?
The primary outcome of the trial will be the change in
mean systolic blood pressure (mmHg) between baseline
and each follow up point (6 months and 12 months),
measured in the surgery by the research team. Additional
secondary outcomes will include change in mean diastolic
blood pressure, adverse events (side effects, anxiety),
health behaviours, illness perceptions, beliefs about med-
ication, medication compliance, patient satisfaction, costs
and reasons for non-participation as well as the qualita-
tive analysis and health economic modelling beyond the
trial outcomes.
Study Design and Setting
TASMINH2 is a primary care based, unblinded, ran-
domised controlled trial with embedded economic and
qualitative analyses in order to evaluate the costs and
effects of increasing patient involvement in blood pres-
sure management.
Ethical considerations
Full ethical approval for this trial has been obtained from
Sandwell and West Birmingham local ethics committee
(reference; 05/Q2709/103), whilst site specific ethical
approval and R & D approval was obtained from the rele-
vant local ethics committees and Primary Care Trusts. A
trial steering group will monitor study progress.
Trial Interventions
Usual care will consist of the participant seeing their Gen-
eral Practitioner (GP) (Family Physician) and/or nurse
periodically for blood pressure measurement and/or
adjustment of medication at the discretion of the GP.
Self-management will consist of self-monitoring of blood
pressure with electronic transmission of readings, and self
titration of medication dependant on the self-monitoring
readings.
Blood pressure self-monitoring
Participants will be trained to monitor their blood pres-
sure using an automated electronic sphygmomanometer.
Home readings will be transmitted to the research team
via the telemonitoring system. Patients will self-monitor
blood pressure daily for the first week of each month of
the study. They will be provided with a guideline that con-
tains simple colour coded instructions. Very high or very
low readings will require checking by the participant's
practice. Four or more above target readings in two con-
secutive months will require a change in medication.
Below target readings will simply require further monitor-
ing the following month.
Target Blood Pressure
Target blood pressures will be based on the NICE hyper-
tension guideline with adjustment of 10/5 mmHg as rec-
ommended by the British Hypertension Society to reflect
home as compared to office readings. [21,22] People
without diabetes will have a home target of ≤130/85
mmHg. People with diabetes or CKD stage 3–5 will have
target blood pressures of ≤130/75 mmHg to take into
account the lower NICE recommendations.
Telemonitoring
Participants will be trained in the use of the telemonitor-
ing equipment at baseline and home visits (practical tech-
nical help) will be available if required to set up
equipment. The equipment consists of a standard vali-
dated automated electronic sphygmomanometer (Omron
705-IT) with a modem for telemonitoring (Melexis I-
modem). Blood pressure data (including time and date)
will be transferred to the research team from the memory
of the electronic sphygmomanometer via an internet con-
nection. Practices will receive summary data from the
research team once each month, by report to allow incor-
poration into clinical records systems. In addition, blood
pressure recordings will also be available to patients via a
secure internet site which will summarise individual
patient's monitoring results.
Self-titration of medication
Each participant will be given an individually tailored two
step self management algorithm through which to adjust
medication according to measured blood pressure. The
choice of medication changes will be decided in conjunc-
tion with their own GP. Each step will represent a single
medication change (additional medication or increased
dose) that will be made following raised readings in two
consecutive months. Medication choice will remain that
of the GP who will be provided with a copy of the NICE
hypertension management algorithm to aid choice of
medication. If patients have used both steps of their self-
management algorithm they will return to the GP and a
new two step plan will be devised. As the study will last for
12 months, patients will not require any more than two
such management plans. Any additional monitoring (for
instance blood tests or urinalysis) will be the responsibil-
ity, and at the discretion, of the GP.
Non-Participation
Included with the letter of invitation to take part in the
trial, will be a form for people to voluntarily return should
they wish to decline the invitation. As well as asking for
their reasons for wishing to decline, this form will also
seek permission to send a further questionnaire and/or
gain their permission for the research team to have access
to their medical records. The further questionnaire will be
similar to that which will be used in the research clinics/
follow-up sessions with people enrolled in the study. Fol-Page 4 of 9
(page number not for citation purposes)
BMC Cardiovascular Disorders 2009, 9:6 http://www.biomedcentral.com/1471-2261/9/6lowing-up those who decline to take part will provide use-
ful information regarding the generalisability of the trial
results, as well as providing a greater insight into the rea-
sons why people may not wish to self-manage their hyper-
tension.
Study Population, Sampling and Recruitment Procedure
The study population will comprise of people with poorly
controlled treated hypertension managed in primary care.
Eligibility criteria will be age between 35–85, treated
hypertension, and blood pressure greater than 140/90.
Exclusion criteria will be inability to self-monitor (includ-
ing diagnosis of dementia, score of >10 on short orienta-
tion memory concentration test), postural hypotension
(systolic blood pressure drop >20 mmHg), more than two
antihypertensive medications, terminal disease, and
blood pressure not managed by their GP. (see Table 2)
Eligible patients will be identified from around 15 general
practices in the West Midlands area drawn from the Mid-
lands Research Practices Consortium (MidReC).[23] A
member of the research team will conduct a practice-
based computer search to identify patients that fulfil the
eligibility criteria. General Practitioners will be asked to
check these computer generated lists to remove people
who are known to have terminal illness, those not man-
aged by the GP or who are thought by the GP to be unsuit-
able for the study. Previous experience from the
TASMINH trial suggests that around 25–30% of people
receiving treatment for hypertension will take part in a
study such as that proposed.[18] We plan to recruit
patients from each practice over a 2–3 week period before
moving on to the next practice. Assuming 40 patients per
practice are recruited then around 50 will need to be
screened and so at least 200 will need to be invited.
Participants who withdraw from the trial will not be
replaced, but asked if they are prepared to continue to
attend follow-up clinics. Analysis will be by intention to
treat.
Randomisation
Randomisation of patients with uncontrolled hyperten-
sion will be to either usual care or self-management of
their hypertension and will take place centrally via tele-
phone or internet using the process of minimisation tak-
ing into account practice, sex, diabetic/chronic kidney
disease status, baseline blood pressure and age.
Study Clinics and Flow through Study
At baseline all patients will attend a clinic at which the
study will be explained, informed consent gained and
questionnaires regarding demographics, past medical his-
tory, self-efficacy and attitudinal compliance will be com-
pleted (Table 3). Measurement of blood pressure and BMI
will also be performed and baseline economic data col-
lected. Patients will be randomised to either usual care or
self-management. People randomised to usual care will
be asked to book an appointment approximately one
week later for a medication review with their usual GP.
People randomised to self-management will be asked to
book an appointment for a group training session where
they will be trained to use an electronic sphygmomanom-
eter and the telemonitoring system. After the group train-
ing session, patients will be asked to practice at home
using their blood pressure monitors and telemonitoring
system, and return approximately one week later for an
individual training session which will cover the self-titra-
tion part of the intervention. If necessary a third training
session will be included for additional support. Following
satisfactory training (assessed by one of the research
team), patients will be asked to make an appointment
with their GP to establish a two step management plan for
any potential medication changes. Patients not judged to
be able to self-manage will be given the option to self-
monitor alone.
All patients will be asked to attend two follow-up clinics;
one at 6 months and one at 12 months. Each clinic will be
timetabled for approximately half an hour, in which time
patients will have their blood pressure measured by the
Table 2: Inclusion and Exclusion Criteria
Inclusion Criteria
Age between 35–85
Treated hypertension (diagnostic code for hypertension plus prescription for antihypertensive medication)
Blood pressure greater than 140/90 at baseline
Willingness to self monitor and self manage
Exclusion Criteria
Inability to self monitor (including diagnosis of dementia, score of >10 on short orientation memory concentration test)
Current prescription for more than two antihypertensive medications
Terminal disease
Blood pressure not managed by their General Practitioner
Postural Drop > 20 mmHg systolicPage 5 of 9
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sphygmomanometer, and will be asked to complete a
questionnaire similar to that completed at baseline. Addi-
tionally, the research team will check that patients in the
intervention arm are using the blood pressure monitors
correctly. This is shown in Figure 1.
Sample size considerations
A sample size of 191 people per group is required for 90%
power assuming a standard deviation of 15 mmHg and a
difference in reduction of blood pressure of at least 5
mmHg between intervention and control groups. A reduc-
tion of 5 mmHg systolic blood pressure is plausible in
comparison with other studies of self-monitoring of
blood pressure and should result in around 19% reduc-
tion in stroke risk. Clinic measurements are used as the
primary end point as these are comparable to most treat-
ment studies. Based on the drop out rate from the initial
TASMINH self monitoring trial, and taking into account
the additional requirements of this trial, a 20% drop out
rate during follow-up is assumed, meaning that a sample
size of 239 per group will need to be randomised, i.e., 478
people. We estimate that between 10–15 practices will be
required i.e., 35–50 patients per practice.
Statistical Analysis
Analysis will be on an intention to treat basis for complete
cases. A sensitivity analysis will examine the potential
effect of missing data. This will include replacement of
missing data by the most recent previous data or by the
mean of the series. The principal analysis will be per-
formed using both raw and adjusted data and will be per-
formed at the end of the trial after all data has been
collected. The primary analysis will be using general linear
modelling (GLM) to compare intervention and control
systolic blood pressure at follow-up adjusting for baseline
blood pressure, practice (as a random effect), diabetic or
CKD status and sex. Planned sub group analyses will be of
diabetic vs non-diabetic patients, older vs younger (65 as
threshold), males vs females, better controlled at baseline
vs worse controlled at baseline (> vs < 155 mmHg systo-
lic).
Economic analysis
The cost analysis will include all key resources associated
with the self-management intervention and related health
and social care services, and will adopt a broad perspective
to include NHS, social care and patient costs. The implica-
tion of this being that we will measure the basic set-up
and delivery costs of the self-management package, in
addition to costs falling on other health and social care
agencies and the research participants themselves. Health
sector cost data (consultations, medications, referrals)
will be collected prospectively by routine practice compu-
ter systems and downloaded by the research team at the
final follow up visit. Intervention costs, including equip-
ment and training, will be collected by the research team.
Patient costs and broader social care resource use will be
collected using a modified version of a patient cost ques-
tionnaire used successfully by the researchers in other set-
tings. Unit cost data will be ascertained for consultation
and referral costs for PCT and system modelling. Drug
costs will be extracted from a contemporaneous BNF.
Table 3: Data Collection at Study Clinics
Baseline Only:
1. Demographic questions; including race, occupation, marital status, employment, education,
2. Length of hypertension
3. Past medical history
4. Contraindications/intolerance to antihypertensives
5. Short orientation memory concentration test[29]
6. Height
7. Current self monitoring behaviour
Baseline and subsequent follow up
1. Current antihypertensive medications
2. Symptom section of the Illness Perception Questionnaire [30]
3. Weight
4. New medical history (in last 6 months)
5. Preference for blood pressure measurement methods
6. Beliefs About Medicines Questionnaire [31]
7. Medication Compliance sub-scale of the Hill-Bone Compliance to High Blood Pressure Medication Scale [32]
8. Short-form of the State-Trait Anxiety inventory [33]
9. EQ5-D [34]
10. Godin's Exercise Questionnaire [35]
11. Questions on smoking, alcohol consumption and salt intake
12. Economic data (referrals, consultations, resource use, willingness to pay)
13. Blood Pressure (sitting plus standing at baseline only)Page 6 of 9
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Flow through the studyigure 1
Flow through the study.
Intervention vs 
control
Study End Points 
Primary Care 
follow up 
Practice clinical system searches for potentially eligible participants:  
Age 35-85 
Hypertension 
Antihypertensive treatment (? 2 antihypertensive medications) 
Last BP > 140/90 
Baseline Clinic: Explanation of study, baseline data 
collection and randomisation 
Intervention group attend both a 
group and individual training 
session
Control: 
Usual care 
Medication review with GP 
Self management plan agreed 
Medication review with GP 
Week 1 
Usual Care Self monitor for one week each 
month
Self titrate medication 
according to agreed plan 
Follow up with GP dependent 
on self management algorithm 
Follow up as decided  
by GP 
6 and 12 month follow up plus 
economic data collection 
GPs check list generated for personal knowledge of 
people likely to be unsuitable: 
Terminally ill, likely to be unable to self manage, 
otherwise unsuitable 
6 and 12 month follow up plus 
economic data collection 
BMC Cardiovascular Disorders 2009, 9:6 http://www.biomedcentral.com/1471-2261/9/6The economic analysis will involve use of cost-conse-
quences analysis, [24] whereby important aspects of costs
and benefits will be analysed and described in their natu-
ral units (e.g., incidence of stroke or diabetes complica-
tions). In addition, the use of the EQ-5D instrument in
the battery of outcome measures also allows a within-trial
cost-utility analysis (CUA) to be undertaken, with benefits
aggregated in terms of quality-adjusted life years (QALYs).
The project will also have a modelling component, the
main purpose of which is to allow for extrapolation
beyond the observed outcomes (i.e. the use of a model-
ling framework provides the opportunity to predict
longer-term outcomes based on the study results). Such
longer-term outcomes include: patient survival, longer-
term quality of life and the full costs associated with long-
term events.
A cost benefit analysis will be performed using willing-
ness-to-pay data collected through a postal survey towards
the end of the trial. These approaches will allow us to cap-
ture in a quantitative manner the broader non-health ben-
efits of self-management.
Qualitative Sub Study
Qualitative participants and sampling
Purposive sampling will be used to choose patients (both
intervention and control), informal carers and healthcare
professionals (up to 20 of each) to allow a wide range of
views and experiences of self-monitoring. This will be fol-
lowed by seeking a further theoretical sample within each
group with selection guided by emerging data analysis in
order to extend and challenge earlier data and interpreta-
tion, and test the integrity and credibility of the develop-
ing analysis.[25] This theoretical sample may include
individuals with particular experiences that it becomes
important to seek as the analysis develops. It is anticipated
that up to 10 further respondents from each of patients,
carers and professionals may be sought in this way (max-
imum 90 participants), before interviewing is no longer
generating new concepts i.e. theoretical saturation.[26]
One to one interviews
Data from patients and informal carers will be collected
by confidential, face-to-face interview in patients' own
homes, and from healthcare professionals in their GP
practice using an interview topic prompt.[27] Patients and
informal carers will be interviewed after approximately 6
months in the study. The interviews will follow broad
topic areas based upon the study objectives and previous
experience of self-monitoring,[18] but encourage
respondents to discuss their perceptions and experiences
freely. Topics will include: previous experience of self-
monitoring of hypertension; views on the monitoring
equipment, training, written instructions and guidelines;
concerns about ability to self-manage; concerns about
adjusting medication; support from family and healthcare
professionals during self-management; effect of self-man-
agement on daily life and lifestyle changes; benefits and
problems with self-management; views on medication.
Their experience of self-management either as user, infor-
mal carer or professional will be specifically focussed on
and explored in depth. The acceptability of self-manage-
ment programmes and any preference they initially had
for standard care or self-management will be explored.
All interviews will be audio-taped and transcribed and
entered into the NVivo software package for qualitative
data analysis.
Qualitative analysis
Constant comparative analysis will be used to interpret
the data.[28] To maximise theoretical sensitivity, research-
ers from different disciplinary and professional back-
grounds will contribute to the development of the
analysis and conceptual framework.[26] Coding processes
will be aided by application of the NVivo software in iden-
tifying emerging key categories and concepts from the
data.[26] These will be compared across the different
interview data sources and established concepts in the lit-
erature. Data collection and analysis will be iterative,
occurring as data collection in the interviews proceeds
with new data being used to challenge, assess or confirm
the emerging analysis. Concepts identified will be inte-
grated into themes providing a structure for presentation
of findings.
Discussion
The results of this trial will be directly applicable to pri-
mary care in the UK. As only half of the approximately
12% of the adult population who are receiving treatment
for hypertension are controlled to recognised targets,
should self management of hypertension with telemoni-
toring be found to be a successful strategy, then it would
be applicable to many hundreds of thousands of individ-
uals in the UK and beyond.
We anticipate that the potential risks of this study are low
and similar to those attributable to usual care. Particular
issues are where a patient finds an excessively high or low
reading and the possibility of increased anxiety due to the
study. The patient guideline will advise contact with the
supervising physician or nurse in the case of excessively
high or low readings. Training of participants will cover
repeated measurements in the case of unusually high or
low readings and a helpline will be available should sub-
jects require advice over and above that available in the
guideline. We will carefully collect data on adverse events.
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